AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Magnesium ions and barium coating of colonic mucosa: Is it a simple question of viscosity?
Authors: Cittadini, G Gallo, A De Cicco, E Giasotto, V Dogliotti, L Cittadini, G
Citation: G. Cittadini et al., Magnesium ions and barium coating of colonic mucosa: Is it a simple question of viscosity?, EUR RADIOL, 11(8), 2001, pp. 1429-1432
Repetita iuvant - INTACC (Intergruppo Italiano Terapia Adiuvante Carcinomadel Colon)
Authors: Di Costanzo, F Gasperoni, S Falcone, A Dogliotti, L Frassinetti, L Bruzzi, P Rosso, R
Citation: F. Di Costanzo et al., Repetita iuvant - INTACC (Intergruppo Italiano Terapia Adiuvante Carcinomadel Colon), ANN ONCOL, 12(9), 2001, pp. 1331-1331
Neuroendocrine oncology - Biological and clinical aspects - 22-24 March 2000 - Turin, Italy - Introduction
Authors: Dogliotti, L Angeli, A Abrahamsson, PA Lamberts, S
Citation: L. Dogliotti et al., Neuroendocrine oncology - Biological and clinical aspects - 22-24 March 2000 - Turin, Italy - Introduction, ANN ONCOL, 12, 2001, pp. S1-S2
Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience
Authors: Stivanello, M Berruti, A Torta, M Termine, A Tampellini, M Gorzegno, G Angeli, A Dogliotti, L
Citation: M. Stivanello et al., Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience, ANN ONCOL, 12, 2001, pp. S73-S77
The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy
Authors: Dogliotti, L Tampellini, M Stivanello, A Gorzegno, G Fabiani, L
Citation: L. Dogliotti et al., The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy, ANN ONCOL, 12, 2001, pp. S105-S109
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma
Authors: Berruti, A Dogliotti, L Mosca, A Gorzegno, G Bollito, E Mari, M Tarabuzzi, R Poggio, M Torta, M Fontana, D Angeli, A
Citation: A. Berruti et al., Potential clinical value of circulating chromogranin A in patients with prostate carcinoma, ANN ONCOL, 12, 2001, pp. S153-S157
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma
Authors: Bollito, E Berruti, A Bellina, A Mosca, A Leonardo, E Tarabuzzi, R Cappia, S Mari, M Tampellini, M Fontana, D Gubetta, L Angeli, A Dogliotti, L
Citation: E. Bollito et al., Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma, ANN ONCOL, 12, 2001, pp. S159-S164
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretrested metastatic breast cancer patients. A multicenter phase II trial
Authors: Donadio, M Manzin, E Berruti, A Bottini, A Gorzegno, G Danese, S DeFabiani, E Sarobba, MG Lorusso, V Castiglione, F Moro, G Bertetto, O Bumma, C Dogliotti, L
Citation: M. Donadio et al., Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretrested metastatic breast cancer patients. A multicenter phase II trial, CANC CHEMOT, 47(5), 2001, pp. 391-396
Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients
Authors: Berruti, A Dogliotti, L Mosca, A Tarabuzzi, R Torta, M Mari, M Gorzegno, G Fontana, D Angeli, A
Citation: A. Berruti et al., Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients, PROSTATE, 47(3), 2001, pp. 205-211
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients withoperable disease
Authors: Fiorentino, C Berruti, A Bottini, A Bodini, M Brizzi, MP Brunelli, A Marini, U Allevi, G Aguggini, S Tira, A Alquati, P Olivetti, L Dogliotti, L
Citation: C. Fiorentino et al., Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients withoperable disease, BREAST CANC, 69(2), 2001, pp. 143-151
Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates
Authors: Berruti, A Dogliotti, L Tucci, M Tarabuzzi, R Fontana, D Angeli, A
Citation: A. Berruti et al., Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates, J UROL, 166(6), 2001, pp. 2023-2031
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acidin the treatment of patients with advanced colorectal carcinoma - A phase I study
Authors: Garufi, G Dogliotti, L D'Attino, RM Tampellini, M Aschelter, AM Pugliese, P Perrone, M Nistico, C Comis, S Terzoli, E
Citation: G. Garufi et al., Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acidin the treatment of patients with advanced colorectal carcinoma - A phase I study, CANCER, 91(4), 2001, pp. 712-720
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
Authors: Bottini, A Berruti, A Bersiga, A Brizzi, MP Bruzzi, P Aguggini, S Brunelli, A Bolsi, A Bolsi, G Allevi, G Generali, D Betri, E Bertoli, G Alquati, P Dogliotti, L
Citation: A. Bottini et al., Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer, BR J CANC, 85(8), 2001, pp. 1106-1112
Laboratory tests for neuroendocrine tumours
Authors: Seregni, E Ferrari, L Stivanello, M Dogliotti, L
Citation: E. Seregni et al., Laboratory tests for neuroendocrine tumours, Q J NUCL M, 44(1), 2000, pp. 22-41
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
Authors: Bottini, A Berruti, A Bersiga, A Brizzi, MP Brunelli, A Gorzegno, G DiMarco, B Aguggini, S Bolsi, G Cirillo, F Filippini, L Betri, E Bertoli, G Alquati, P Dogliotti, L
Citation: A. Bottini et al., p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients, CLIN CANC R, 6(7), 2000, pp. 2751-2758
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment
Authors: Berruti, A Dogliotti, L Osella, G Cerutti, S Reimondo, G Martino, A Gorzegno, G Catolla, R Angeli, A
Citation: A. Berruti et al., Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment, ONCOL REP, 7(4), 2000, pp. 777-781
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines
Authors: Berruti, A Sperone, P Bottini, A Gorzegno, G Lorusso, V Brunelli, A Botta, M Tampellini, M Donadio, M Mancarella, S De Lena, M Alquati, P Dogliotti, L
Citation: A. Berruti et al., Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines, J CL ONCOL, 18(19), 2000, pp. 3370-3377
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
Authors: von der Maase, H Hansen, SW Roberts, JT Dogliotti, L Oliver, T Moore, MJ Bodrogi, I Albers, P Knuth, A Lippert, CM Kerbrat, P Rovira, PS Wersall, P Cleall, SP Roychowdhury, DF Tomlin, I Visseren-Grul, CM Conte, PF
Citation: H. Von Der Maase et al., Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study, J CL ONCOL, 18(17), 2000, pp. 3068-3077
Chronochemotherapy
Authors: Dogliotti, L Garufi, C Iacobelli, S
Citation: L. Dogliotti et al., Chronochemotherapy, TUMORI, 86(3), 2000, pp. S32-S36
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline
Authors: Berruti, A Dogliotti, L Bitossi, R Fasolis, G Gorzegno, G Bellina, M Torta, M Porpiglia, F Fontana, D Angeli, A
Citation: A. Berruti et al., Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline, J UROL, 164(4), 2000, pp. 1248-1253
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer
Authors: Terzolo, M Pia, A Berruti, A Osella, G Ali, A Carbone, V Testa, E Dogliotti, L Angeli, A
Citation: M. Terzolo et al., Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer, J CLIN END, 85(6), 2000, pp. 2234
Circulating neuroendocrine markers in patients with prostate carcinoma
Authors: Berruti, A Dogliotti, L Mosca, A Bellina, M Mari, M Torta, M Tarabuzzi, R Bollito, E Fontana, D Angeli, A
Citation: A. Berruti et al., Circulating neuroendocrine markers in patients with prostate carcinoma, CANCER, 88(11), 2000, pp. 2590-2597
Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells
Authors: Villa, R Orlandi, L Berruti, A Dogliotti, L Zaffaroni, N
Citation: R. Villa et al., Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells, INT J ONCOL, 14(1), 1999, pp. 133-138
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
Authors: von der Maase, H Andersen, L Crino, L Weinknecht, S Dogliotti, L
Citation: H. Von Der Maase et al., Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial, ANN ONCOL, 10(12), 1999, pp. 1461-1465
Letter to the Editor
Authors: Garufi, C Dogliotti, L Terzoli, E Focan, C Smaaland, R Chollet, P Perpoint, B Levi, F
Citation: C. Garufi et al., Letter to the Editor, TUMORI, 85(2), 1999, pp. 149-150
Risultati: 1-25 | 26-33